J. Bartley

发表

Protein and calorie intakes in adult and pediatric subjects with urea cycle disorders participating in clinical trials of glycerol phenylbutyrate☆

Ingrid L. Rudolph-Angelich, N. Longo, Brendan H. Lee, 2016, Molecular genetics and metabolism reports.

Nasal Levels of Nitric Oxide as an Outcome Variable in Allergic Upper Respiratory Tract Disease: Influence of Atopy and Hayfever on nNO

A. Wells, J. Kolbe, W. Fergusson, 2006, American journal of rhinology.

Increased nitric oxide production in the respiratory tract in asymptomatic pacific islanders: an association with skin prick reactivity to house dust mite.

A. Wells, J. Kolbe, W. Fergusson, 2000, The Journal of allergy and clinical immunology.

Normal Adult Values, Diurnal Variation, and Repeatability of Nasal Nitric Oxide Measurement

A. Wells, J. Bartley, J. Kolbe, 1999, American journal of rhinology.

Urinary phenylacetylglutamine (U-PAGN) concentration as biomarker for adherence in patients with urea cycle disorders (UCD) treated with glycerol phenylbutyrate

Brendan H. Lee, G. Diaz, B. Scharschmidt, 2015, Molecular genetics and metabolism reports.

Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate

S. Cederbaum, N. Longo, Brendan H. Lee, 2013, Hepatology.

Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.

D. Rockey, N. Longo, G. Diaz, 2013, Molecular genetics and metabolism.

Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders.

J L Merritt, B F Scharschmidt, S. Cederbaum, 2012, Molecular genetics and metabolism.

Nutrition and the Upper Respiratory Tract

J. Bartley, 2013 .

Glutamine and hyperammonemic crises in patients with urea cycle disorders.

M. Marino, N. Longo, Brendan H. Lee, 2016, Molecular genetics and metabolism.

Nasal Pulmonary Interactions

Conroy A Wong, J. Bartley, 2013 .

BLOOD AMMONIA AND GLUTAMINE AS PREDICTORS OF HYPERAMMONEMIC CRISES IN UREA CYCLE DISORDER PATIENTS

M. Marino, S. Cederbaum, J. Vockley, 2014, Genetics in Medicine.

Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.

D. Rockey, N. Longo, Brendan H. Lee, 2013, Molecular genetics and metabolism.

Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate

S. Cederbaum, N. Longo, Brendan H. Lee, 2013, Hepatology.

Self-reported treatment-associated symptoms among patients with urea cycle disorders participating in glycerol phenylbutyrate clinical trials.

M. Marino, S. Cederbaum, J. Vockley, 2015, Molecular genetics and metabolism.

BLOOD AMMONIA AND GLUTAMINE AS PREDICTORS OF HYPERAMMONEMIC CRISES IN UREA CYCLE DISORDER PATIENTS

S. Cederbaum, J. Vockley, N. Longo, 2014, Genetics in Medicine.